Beam Therapeutics, a biotechnology company specializing in the development of precision genetic medications through base editing, has announced that Terry-Ann Burrell, its Chief Financial Officer, will be departing the company. Burrell will depart the organization to assume the position of Vice Chairman of Investment Banking at JPMorgan Chase. In order to facilitate a planned transition procedure, Beam Therapeutics has initiated the search for a successor. “Terry-Ann has been an invaluable member of our team over the last five years, and her leadership was instrumental in the success of our IPO, the build-out of our finance and corporate affairs functions, and the development of Beam’s organization and culture,” stated John Evans, CEO of Beam Therapeutics.
Burrell's tenure at Beam Therapeutics has been distinguished by numerous accomplishments, such as the establishment of a robust financial and corporate infrastructure and the successful passage of the company through its initial public offering. Her contributions have played a critical role in the organization's development and culture. Beam Therapeutics continues to prioritize its quest to create precise genetic medications through the implementation of base editing technology. The company is dedicated to ensuring a smooth transition in financial leadership as it advances its strategic objectives and innovation in genetic medicine, a commitment reflected in its scientific and corporate activities.
